Handelsinvest Investeringsforvaltning Exits Position in Coherus Biosciences Inc (CHRS)

Coherus Biosciences Inc (CHRS) : Handelsinvest Investeringsforvaltning has sold out all of its stake in Coherus Biosciences Inc during the most recent quarter, according to the disclosure filed by the company on Aug 8, 2016 with the SEC. The investment management company has sold out 14,200 shares of Coherus Biosciences Inc which is valued at $426,710.

Other Hedge Funds, Including , Oxford Asset Management added CHRS to its portfolio by purchasing 43,157 company shares during the most recent quarter which is valued at $1,296,868. Coherus Biosciences Inc makes up approx 0.05% of Oxford Asset Management’s portfolio.Columbus Circle Investors boosted its stake in CHRS in the latest quarter, The investment management firm added 154,086 additional shares and now holds a total of 373,249 shares of Coherus Biosciences Inc which is valued at $10,421,112. Coherus Biosciences Inc makes up approx 0.10% of Columbus Circle Investors’s portfolio. Rhenman Partners Asset Management Ab added CHRS to its portfolio by purchasing 131,357 company shares during the most recent quarter which is valued at $3,667,487. Coherus Biosciences Inc makes up approx 0.59% of Rhenman Partners Asset Management Ab’s portfolio.Simplex Trading boosted its stake in CHRS in the latest quarter, The investment management firm added 372 additional shares and now holds a total of 499 shares of Coherus Biosciences Inc which is valued at $13,024.Handelsbanken Fonder Ab reduced its stake in CHRS by selling 10,000 shares or 18.18% in the most recent quarter. The Hedge Fund company now holds 45,000 shares of CHRS which is valued at $1,054,800. Coherus Biosciences Inc makes up approx 0.04% of Handelsbanken Fonder Ab’s portfolio.

Coherus Biosciences Inc opened for trading at $29.7 and hit $30.3 on the upside on Monday, eventually ending the session at $30.1, with a gain of 2.03% or 0.6 points. The heightened volatility saw the trading volume jump to 4,23,141 shares. Company has a market cap of $1,306 M.

Many Wall Street Analysts have commented on Coherus Biosciences Inc. Citigroup Initiated Coherus Biosciences Inc on Jul 27, 2016 to “Buy”, Price Target of the shares are set at $36.

Coherus BioSciences Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company’s clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF) and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company’s product pipeline includes anti-TNF product candidate CHS-0214 an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials and anti-TNF product candidate CHS-1420 an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate CHS-1701 a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *